Skip Navigation Links

Eli Lilly | Company Information from ICIS

 

Eli Lilly is a major pharmaceutical corporation which develops, manufactures and markets pharmaceutical products. The company has major R&D facilities in seven countries and manufacturing facilities in 13 countries.

 Eli Lilly logo (Source: Eli Lilly)

Eli Lilly will focus on its ‘innovation-driven’ strategy and invest in R&D with the goal of delivering a steady flow of innovative products. The company will also build the capabilities to manufacture these products and market them effectively around the world, and augment its own capabilities and resources through partnerships.

 

Eli Lilly is readying a generation of molecules for the market and restocking its early-stage pipeline. Its strength in developing both small-molecule and large-molecule ‘biotech’ medicines is said to distinguish Eli Lilly from most other major pharmaceutical companies.

 

Headquartered in Indianapolis, Indiana, US, Eli Lilly has approximately 40,360 employees worldwide and net sales in 2009 of $22bn.

 

Download the The ICIS Top 100 Chemical Companies listing here

 

Key Personnel

 

Chairman: John Lechleiter

Member: Michael Cook

Member: Michael Eskew

Member: Martin Feldstein

Member: George Fisher

Member: Erik Fyrwald

Member: Alfred Gilman

Member: Karen Horn

Member: Ellen Marram

Member: Franklyn Prendergast

Member: Kathi Seifert

 

 

Contacts

 

Eli Lilly & Company 
Lilly Corporate Centre 
PO Box 88665
Indianapolis, Indiana 46285
US
 

Tel: +1 317 276 2000
Fax: +1 317 277 6139

 

www.lilly.com 

Eli Lilly Company Structure

Eli Lilly is a major pharmaceutical corporation which develops pharmaceutical products. The company has major R&D facilities in seven countries. Its R&D facilities are located in Australia, Belgium, Canada, England, Germany, Japan, Singapore, Spain, and the US. It conducts clinical research in more than 60 countries around the world. Manufacturing facilities are located in Brazil, China, Egypt, England, France, Germany, Ireland, Italy, Japan, Korea, Mexico, Pakistan, Puerto Rico, Spain and the US. In addition Eli Lilly operates 14 administrative, manufacturing and R&D plants in the US and Puerto Rico.
More about Eli Lilly Structure

Eli Lilly Strategy & Financial Highlights

Eli Lilly will focus on its ‘innovation-driven’ strategy. The company has built what it states as being ‘one of the most productive R&D organisations in the pharmaceutical industry’. It is currently readying a generation of molecules for the market and restocking its early-stage pipeline. It states that ‘unlike most of its peers’, it does not have any major patent expirations coming up in the next several years. Its strength in developing both small-molecule and large-molecule ‘biotech’ medicines is said to also distinguish Eli Lilly from most other major pharmaceutical companies. (Edited from 'Letter to shareholders' - annual report). ICIS also provides you with key financial data listed in table form. More about Eli Lilly Strategy & Financial Highlights

News:

Get news on Eli Lilly plus the latest chemical news, information, data, market movements and analysis in one place with ICIS news

Search:

Find details on other chemical companies and suppliers with ICIS search

Newsletters:

ICIS offers a range of FREE e-newsletters to ensure that you don't miss out on the latest development and key market intelligence in your industry. If you want the latest news sent to your inbox, sign up for ICIS e-newsletters today.

Plants and projects:

Find out more about current and planned chemical plants and projects by subscribing to our comprehensive database

 
Free trial to ICIS
ICIS Chemical Business - ICIS Chemical Business Endpoint
This blog records content for the Endpoint page of ICIS Chemical Business ahead of publication. It is a series of works in progress. To read the definitive version of the column subscribe to ICIS Chemical Business on paper and on line

Insight

INSIGHT: Small change could mean big shift in US home sales
“This will make credit more available for folks on the fringe and make mortgage loans more affordable in general.” more

VIDEO: ICIS special report on the fertilizers markets

More...

We welcome your feedback. Please feel free to send us your comments on any aspect of this site. Click here to make your comments.